Alkermes (ALKS) Cash & Equivalents (2010 - 2026)

Alkermes (ALKS) has 17 years of Cash & Equivalents data on file, last reported at $351.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 12.07% year-over-year to $351.6 million in Q1 2026; TTM through Mar 2026 was $351.6 million, a 12.07% decrease from a year earlier, with the FY2025 full-year figure at $388.6 million, up 33.46% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $351.6 million, down from $388.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ALKS reached as high as $665.8 million in Q2 2023 and fell as low as $254.6 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $418.1 million across 5 years, with a median of $396.3 million in 2024.
• Across the five-year window, Cash & Equivalents soared 161.46% in 2023 and sank 38.82% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $292.5 million in 2022, then jumped by 56.41% to $457.5 million in 2023, then tumbled by 36.36% to $291.1 million in 2024, then soared by 33.46% to $388.6 million in 2025, then slipped by 9.53% to $351.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $351.6 million in Q1 2026, $388.6 million in Q4 2025, and $616.4 million in Q3 2025.